Literature DB >> 19133999

5-HT1A receptors are involved in the cannabidiol-induced attenuation of behavioural and cardiovascular responses to acute restraint stress in rats.

Leonardo B M Resstel1, Rodrigo F Tavares, Sabrina F S Lisboa, Sâmia R L Joca, Fernando M A Corrêa, Francisco S Guimarães.   

Abstract

BACKGROUND AND
PURPOSE: Cannabidiol (CBD) is a non-psychotomimetic compound from Cannabis sativa which induces anxiolytic- and antipsychotic-like effects in rodents. These effects could be mediated by facilitation of the endocannabinoid system or by the activation of 5-HT(1A) receptors. As either of these mechanisms could promote adaptation to inescapable stress, the aim of the present work was to test the hypothesis that CBD would attenuate the autonomic and behavioural consequences of restraint stress (RS). We also investigated if the responses to CBD depended on activation of 5-HT(1A) receptors. EXPERIMENTAL APPROACH: Male Wistar rats received i.p. injections of vehicle or CBD (1, 10 or 20 mg kg(-1)) and 30 min later were submitted to 60 min of restraint where their cardiovascular responses were recorded. The protocol of the second experiment was similar to the first one except that animals received i.p. injections of the 5-HT(1A) receptor antagonist WAY100635 (0.1 mg kg(-1)) before CBD treatment and exposure to restraint. 24 h later they were also tested in the elevated plus-maze (EPM), an animal model of anxiety. KEY
RESULTS: Exposure to RS increased blood pressure and heart rate and induced an anxiogenic response in the EPM 24 h later. These effects were attenuated by CBD. WAY100635 by itself did not change the cardiovascular and anxiogenic response to RS, but blocked the effects of CBD. CONCLUSION AND IMPLICATIONS: The results suggest that CBD can attenuate acute autonomic responses to stress and its delayed emotional consequences by facilitating 5-HT(1A) receptor-mediated neurotransmission.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19133999      PMCID: PMC2697769          DOI: 10.1111/j.1476-5381.2008.00046.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  73 in total

1.  Guide to Receptors and Channels (GRAC), 3rd edition.

Authors:  S P H Alexander; A Mathie; J A Peters
Journal:  Br J Pharmacol       Date:  2008-03       Impact factor: 8.739

Review 2.  An assessment of anxiolytic drug screening tests: hormetic dose responses predominate.

Authors:  Edward J Calabrese
Journal:  Crit Rev Toxicol       Date:  2008       Impact factor: 5.635

3.  Restraint-induced hypoactivity in an elevated plus-maze.

Authors:  C M Padovan; F S Guimarães
Journal:  Braz J Med Biol Res       Date:  2000-01       Impact factor: 2.590

Review 4.  Marihuana chemistry.

Authors:  R Mechoulam
Journal:  Science       Date:  1970-06-05       Impact factor: 47.728

5.  Delayed treatment with cannabidiol has a cerebroprotective action via a cannabinoid receptor-independent myeloperoxidase-inhibiting mechanism.

Authors:  Kazuhide Hayakawa; Kenichi Mishima; Masanori Nozako; Mai Hazekawa; Keiichi Irie; Masayuki Fujioka; Kensuke Orito; Kohji Abe; Nobuyoshi Hasebe; Nobuaki Egashira; Katsunori Iwasaki; Michihiro Fujiwara
Journal:  J Neurochem       Date:  2007-04-16       Impact factor: 5.372

6.  5-HT1A receptor activation before acute stress counteracted the induced long-term behavioral effects.

Authors:  J Rioja; L J Santín; M García; A Doña; L De Pablos; M I Cuadrado; F J Alcalde; S González-Barón; J A Aguirre
Journal:  Ann N Y Acad Sci       Date:  2004-06       Impact factor: 5.691

7.  Cannabidiol lacks the vanilloid VR1-mediated vasorespiratory effects of capsaicin and anandamide in anaesthetised rats.

Authors:  Daniel S McQueen; Susan M Bond; Paula J W Smith; Kia Balali-Mood; Darren Smart
Journal:  Eur J Pharmacol       Date:  2004-05-03       Impact factor: 4.432

8.  Involvement of 5HT1A receptors in the anxiolytic-like effects of cannabidiol injected into the dorsolateral periaqueductal gray of rats.

Authors:  Alline Cristina Campos; Francisco Silveira Guimarães
Journal:  Psychopharmacology (Berl)       Date:  2008-05-01       Impact factor: 4.530

9.  Reduced anxiety-related behaviour in transgenic mice overexpressing serotonin 1A receptors.

Authors:  Heike Kusserow; Benjamin Davies; Heide Hörtnagl; Ingo Voigt; Thomas Stroh; Bettina Bert; Dong Rui Deng; Heidrun Fink; Rüdiger W Veh; Franz Theuring
Journal:  Brain Res Mol Brain Res       Date:  2004-10-22

Review 10.  Modulation of stress consequences by hippocampal monoaminergic, glutamatergic and nitrergic neurotransmitter systems.

Authors:  Sâmia Regiane Lourenço Joca; Frederico Rogério Ferreira; Francisco Silveira Guimarães
Journal:  Stress       Date:  2007-08       Impact factor: 3.493

View more
  77 in total

Review 1.  Cannabidiol for neurodegenerative disorders: important new clinical applications for this phytocannabinoid?

Authors:  Javier Fernández-Ruiz; Onintza Sagredo; M Ruth Pazos; Concepción García; Roger Pertwee; Raphael Mechoulam; José Martínez-Orgado
Journal:  Br J Clin Pharmacol       Date:  2013-02       Impact factor: 4.335

2.  Comment on: "Anxiogenic-like effects of chronic cannabidiol administration in rats" (Elbatsh MM, Assareh N, Marsden CA, Kendall DA, Psychopharmacology 2012).

Authors:  Anand Gururajan
Journal:  Psychopharmacology (Berl)       Date:  2012-07-04       Impact factor: 4.530

Review 3.  Cannabidiol regulation of emotion and emotional memory processing: relevance for treating anxiety-related and substance abuse disorders.

Authors:  Jonathan L C Lee; Leandro J Bertoglio; Francisco S Guimarães; Carl W Stevenson
Journal:  Br J Pharmacol       Date:  2017-03-09       Impact factor: 8.739

4.  A single dose of cannabidiol reduces blood pressure in healthy volunteers in a randomized crossover study.

Authors:  Khalid A Jadoon; Garry D Tan; Saoirse E O'Sullivan
Journal:  JCI Insight       Date:  2017-06-15

Review 5.  A review on animal models for screening potential anti-stress agents.

Authors:  Amteshwar Singh Jaggi; Nitish Bhatia; Naresh Kumar; Nirmal Singh; Preet Anand; Ravi Dhawan
Journal:  Neurol Sci       Date:  2011-09-17       Impact factor: 3.307

6.  Effect of prior foot shock stress and Δ9-tetrahydrocannabinol, cannabidiolic acid, and cannabidiol on anxiety-like responding in the light-dark emergence test in rats.

Authors:  Erin M Rock; Cheryl L Limebeer; Gavin N Petrie; Lauren A Williams; Raphael Mechoulam; Linda A Parker
Journal:  Psychopharmacology (Berl)       Date:  2017-04-20       Impact factor: 4.530

Review 7.  Plant-based medicines for anxiety disorders, part 2: a review of clinical studies with supporting preclinical evidence.

Authors:  Jerome Sarris; Erica McIntyre; David A Camfield
Journal:  CNS Drugs       Date:  2013-04       Impact factor: 5.749

8.  Cannabidiol potentiates Δ⁹-tetrahydrocannabinol (THC) behavioural effects and alters THC pharmacokinetics during acute and chronic treatment in adolescent rats.

Authors:  Charlotte Klein; Emily Karanges; Adena Spiro; Alexander Wong; Jarrah Spencer; Thanh Huynh; Nathan Gunasekaran; Tim Karl; Leonora E Long; Xu-Feng Huang; Kelly Liu; Jonathon C Arnold; Iain S McGregor
Journal:  Psychopharmacology (Berl)       Date:  2011-06-11       Impact factor: 4.530

Review 9.  Drug discovery strategies that focus on the endocannabinoid signaling system in psychiatric disease.

Authors:  Ryan Wyrofsky; Paul McGonigle; Elisabeth J Van Bockstaele
Journal:  Expert Opin Drug Discov       Date:  2014-12-09       Impact factor: 6.098

10.  Antidepressant-like effects of cannabidiol in mice: possible involvement of 5-HT1A receptors.

Authors:  T V Zanelati; C Biojone; F A Moreira; F S Guimarães; Sâmia R L Joca
Journal:  Br J Pharmacol       Date:  2009-12-04       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.